Publications by authors named "C Meloche"
Background/objectives: Pediatric cancer survivors are at greater risk of cardiometabolic complications than their peers. This study evaluates the preliminary impact of the VIE (Valorization, Implication, Education) intervention, which integrates nutrition, physical activity, and psychological support, on dietary intake and cardiometabolic health among children and adolescents during cancer treatment.
Methods: This comparative study includes pediatric cancer patients recruited to either the VIE intervention group or a control group receiving standard care.
Purpose Of Review: To summarize selected late-breaking science on cardiovascular disease (CVD) prevention presented at the 2024 European Society of Cardiology (ESC) Congress.
Recent Findings: Key studies from the 2024 ESC Congress highlight advances in (CVD) management. Apolipoprotein A-1 infusions reduced risk in acute myocardial infarction patients with high LDL cholesterol.
Purpose Of Review: To summarize selected late-breaking science on cardiovascular (CV) disease prevention presented at the 2024 Scientific Session of the American College of Cardiology (ACC) conference.
Recent Findings: The LIBerate-HR trial showed the efficacy and safety of lerodalcibep, a subcutaneous injection that prevents binding of Pro-Protein Convertase Subtilisin/Kexin (PCSK) 9 to low-density lipoprotein (LDL)-receptors resulting in LDL-cholesterol (LDL-C) lowering in patients at very high risk or high risk of atherosclerotic CV disease (ASCVD). The AEGIS-II randomized patients with type 1 myocardial infarction (MI) with multivessel coronary artery disease and additional CV risk factors and found no benefit in major adverse CV events (MACE) with CSL112, an apolipoprotein A1 infusion shown to increase cholesterol efflux capacity.
Article Synopsis
- Focused on ten notable studies from the 2023 American Heart Association Scientific Sessions, this review summarizes advancements in cardiovascular disease research.
- Included studies evaluated various treatments and interventions, such as semaglutide for weight management in non-diabetic patients, dapagliflozin post-myocardial infarction, and the impact of sodium intake on blood pressure.
- The findings highlight innovative approaches for preventing and managing cardiovascular diseases, emphasizing novel therapies and techniques to improve patient outcomes.
Article Synopsis
- A study was conducted on adult COVID-19 patients hospitalized from February 2020 to October 2022 to identify effective inflammatory biomarkers for assessing patient risk during hospitalization.
- The biomarkers analyzed included suPAR, C-reactive protein (CRP), interleukin-6, procalcitonin, ferritin, and D-dimer; suPAR emerged as the strongest predictor of severe outcomes, such as death or the need for mechanical ventilation.
- A suPAR cutoff of 4.0 ng/mL was found to indicate low risk with high sensitivity and negative predictive value, suggesting it could be a valuable tool for triaging low-risk COVID-19 patients.